



# Core Project R03OD030604



## Details







| Projects        | Name   | Award        | Publications   | Repositories   | Analytics    |
|-----------------|--|--------------|----------------|----------------|--------------|
| 1R03OD030604-01 | Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing | \$297,000.00 | 9 publications | 0 repositories | 0 properties |









## Publications

Published works associated with this project.

| ID   | Title   | Authors           | R<br>C<br>R | SJ<br>R  | Cita<br>tion<br>s | Cit./<br>yea<br>r | Journal                    | Publ<br>ishe<br>d | Updat<br>ed |
|--|---|-------------------|-------------|----------|-------------------|-------------------|----------------------------|-------------------|-------------|
| <a href="#">35337371</a> <a href="#">DOI</a> | Considerations and challenges for sex-aware drug repurposing. | Jennifer L Fisher | 1.<br>46    | 2.<br>03 | 9                 | 4.5               | Biology of Sex Differences | 2,02<br>2         | Oct<br>26,  |

|   |  |  |          |               |   |   |                                  |       |  |
|---|--|--|----------|---------------|---|---|----------------------------------|-------|--|
|   |  | ...4<br>more...<br>Brittany<br>N<br>Lasseigne                        |          |               |   |   |                                  |       | 2024<br>(1<br>mont<br>h ago)               |
| <a href="#">37533331</a> <br><a href="#">DOI</a>      | Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-disease... | Avery S<br>Williams<br>...2<br>more...<br>Brittany<br>N<br>Lasseigne | 1.<br>05 | 0             | 3 | 3 | Cancer Rep<br>(Hoboken)          | 2,023 | Oct<br>26,<br>2024<br>(1<br>mont<br>h ago) |
| <a href="#">36602970</a> <br><a href="#">DOI</a>  | Ten simple rules for using public biological data for your research.                                 | Vishal H<br>Oza<br>...9<br>more...<br>Brittany<br>N<br>Lasseigne     | 0.<br>61 | 1.<br>65<br>2 | 2 | 2 | PLoS<br>Computational<br>Biology | 2,023 | Oct<br>26,<br>2024<br>(1<br>mont<br>h ago) |
| <a href="#">37824797</a> <br><a href="#">DOI</a>  | Computational Advancements in Cancer Combination Therapy Prediction.                                 | Victoria<br>L Flanary<br>...3<br>more...<br>Brittany                 | 0.<br>46 | 2.<br>24<br>9 | 2 | 2 | JCO Precision<br>Oncology        | 2,023 | Oct<br>26,<br>2024<br>(1                   |


|   |  |   |          |               |   |   |                       |           |  |                |
|---|--|---|----------|---------------|---|---|-----------------------|-----------|--|----------------|
|   |  | N<br>Lasseign<br>e  |          |               |   |   |                       |           |  | mont<br>h ago) |
| <a href="#">37217845</a> <br><a href="#">DOI</a>      | Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and... | Elizabet<br>h J Wilk<br>...9<br>more...<br>Brittany<br>N<br>Lasseign<br>e | 0.<br>39 | 1.<br>44<br>6 | 1 | 1 | Molecular<br>Medicine | 2,02<br>3 | Nov 8,<br>2024<br>(1<br>mont<br>h ago)     |                |
| <a href="#">37090499</a> <br><a href="#">DOI</a>     | Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-disease... | Avery S<br>Williams<br>...2<br>more...<br>Brittany<br>N<br>Lasseign<br>e  | 0        | 0             | 0 | 0 | bioRxiv               | 2,02<br>3 | Oct<br>26,<br>2024<br>(1<br>mont<br>h ago) |                |
| <a href="#">37362157</a> <br><a href="#">DOI</a>  | Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets ... | Jennifer<br>L Fisher<br>...2<br>more...<br>Brittany<br>N<br>Lasseign<br>e | 0        | 0             | 0 | 0 | bioRxiv               | 2,02<br>3 | Oct<br>26,<br>2024<br>(1<br>mont<br>h ago) |                |

|   |  |   |   |       |   |   |                               |       |                            |
|---|--|---|---|-------|---|---|-------------------------------|-------|----------------------------|
| <a href="#">38167211</a> <br><a href="#">DOI</a>  | Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets ... | Jennifer L Fisher<br>...2 more...<br>Brittany N Lasseigne | 0 | 0.71  | 0 | 0 | BMC pharmacology & toxicology | 2,024 | Oct 26, 2024 (1 month ago) |
| <a href="#">38531616</a> <br><a href="#">DOI</a>  | Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposi... | Jennifer L Fisher<br>...7 more...<br>Brittany N Lasseigne | 0 | 0.789 | 0 | 0 | FEBS Open Bio                 | 2,024 | Oct 26, 2024 (1 month ago) |

Notes

RCR   [Relative Citation Ratio](#) 

SJR   [Scimago Journal Rank](#) 



Notes

- RepositoryFor storing, tracking changes to, and collaborating on a piece of software.
- PR"Pull request", a draft change (new feature, bug fix, etc.) to a repo.
- Closed/OpenResolved/unresolved.
- Avg Issue/PRAverage time issues/pull requests stay open for before being closed.
- Only the main/default branch is considered for metrics like # of commits.
- # of dependencies is totaled from all manifests in repo, direct and transitive, e.g. package.json + package-lock.json.

## Analytics

Traffic metrics of websites associated with this project.

### Notes

Active Users      [Distinct users who visited the website](#) .

New Users      [Users who visited the website for the first time](#) .

Engaged Sessions      [Visits that had significant interaction](#) .

"Top" metrics are measured by number of engaged sessions.